Ruobing Li

TL;DR: KAE609, at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. vivax or P. falciparum malaria, supporting a once-daily oral dosing regimen.

TL;DR: KAE609 was tolerated in this study, with transient gastrointestinal and genitourinary adverse events of mild to moderate intensity, which increased with rising doses and the high fat food intake did not affect the extent of KAE609 absorption (AUC); however, the Cmax was reduced by around 27%.

TL;DR: KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria.

TL;DR: This first in human randomized, double-blind, placebocontrolled, ascending single and multiple oral dose study was designed to evaluate the safety, tolerability and pharmacokinetics of KAE609 in healthy volunteers.

TL;DR: In this article , a range of systems approaches and methods, such as systems mapping and systems modeling, are used to better characterize the various systems involved in communicating public health-related information can lead to the development of more tailored, precise and proactive communications.